Patents by Inventor John N. Vournakis

John N. Vournakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10765698
    Abstract: This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 8, 2020
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Patent number: 10561677
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 18, 2020
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Publication number: 20190290734
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Barbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John V. VOURNAKIS
  • Patent number: 10383971
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: August 20, 2019
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: Sergio Finkielsztein, John N. Vournakis
  • Publication number: 20190247410
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 15, 2019
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Publication number: 20190209653
    Abstract: Cyclical administration regimens of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15Ra”) to patients enhances IL-15-mediated immune function. Cyclical administration regimens achieve plasma levels of IL-15 above basal levels while minimizing the toxicity associated with IL-15 administration. Cyclical administration regimens are useful in the prevention, treatment, and/or management of cancer, infectious diseases, immunodeficienices and lymphopenia. The cyclical administration regimens can use purified soluble forms of IL-15Ra, cells that recombinantly express soluble forms of IL-15Ra, and compositions comprising complexes of IL-15 covalently or non-covalently bound to soluble forms of IL-15Ra, for propagating, activating and/or differentiating IL-15 responsive cells.
    Type: Application
    Filed: December 13, 2018
    Publication date: July 11, 2019
    Inventors: Barbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John N. VOURNAKIS
  • Patent number: 10335460
    Abstract: Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15R?”) to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. In another specific aspect, the dose escalation regimens are useful for eradicating or reducing HIV in HIV-infected patients.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 2, 2019
    Assignees: NOVARTIS AG, The United States of America Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John N. Vournakis
  • Patent number: 10252040
    Abstract: This invention relates in general to a method and device for facilitating hemostasis and wound healing. In particular, the invention relates to the device comprising a polymeric material disposed on a scaffold that facilitates hemostasis and wound healing. Specifically, the invention contemplates the use of such scaffolds in conjunction with a negative pressure device.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 9, 2019
    Assignees: Marine Polymer Technologies, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Dennis P. Orgill, Giorgio Pietramaggiori, Sergio Finkielsztein, John N. Vournakis
  • Publication number: 20190060348
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 28, 2019
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: Sergio Finkielsztein, John N. Vournakis
  • Patent number: 10206938
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 19, 2019
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Patent number: 10206683
    Abstract: A vascular compression apparatus and method for applying pressure onto an area of a patient generally including a blood vessel and a wound site, such as a blood vessel puncture, after a cannulated procedure for the purpose of controlling bleeding and achieving hemostasis. The vascular compression apparatus includes a handle, a shaft and a pad. The shaft extends generally downward from the center of the bottom side of the handle. The pad is connected generally off-center of its top side to the bottom end of the shaft. The bottom side of the pad is convex to allow the vascular compression device to be rocked back and forth. In use, the pad is generally placed proximal to the catheter insertion site and over the blood vessel containing the catheter. The device is rocked proximally to control blood flow while removing the catheter. After the catheter is removed from the puncture site, the device is rocked distally to the puncture site, where pressure is applied until hemostasis is achieved.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: February 19, 2019
    Assignee: MARINE POLYMER TECHNOLOGIES, INC.
    Inventors: Sergio Finkielsztein, Marco Finkielsztein, John N. Vournakis
  • Publication number: 20180360868
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue.
    Type: Application
    Filed: December 14, 2017
    Publication date: December 20, 2018
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: Sergio Finkielsztein, John N. Vournakis
  • Publication number: 20180099003
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 12, 2018
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Patent number: 9931377
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol? those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: April 3, 2018
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Novartis AG
    Inventors: George N. Pavlakis, John N. Vournakis, Barbara K. Felber, Sergio Finkielsztein
  • Publication number: 20170304354
    Abstract: This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
    Type: Application
    Filed: March 13, 2017
    Publication date: October 26, 2017
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Serglo Finkielsztein
  • Publication number: 20170128382
    Abstract: Provided herein are p-GlcNAc nanoparticle/nucleic acid compositions. In one aspect, the p-GlcNAc nanoparticle/nucleic acid compositions comprise deacetylated poly-N-acetylglucosamine lactate derivative nanoparticles less than 500 nm and a nucleic acid. Also, provided herein are methods for administering a nucleic acid to a subject, the method comprising administering to the subject a p-GlcNAc nanoparticle/nucleic acid composition. In certain embodiments, the p-GlcNAc nanoparticle/nucleic acid composition is administered subcutaneously to the subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: May 11, 2017
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Marina V. Demcheva
  • Patent number: 9642871
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 9, 2017
    Assignee: MARINE POLYMER TECHNOLOGIES, INC.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Publication number: 20160235774
    Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 18, 2016
    Applicant: MARINE POLYMER TECHNOLOGIES, INC.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Publication number: 20160193379
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.
    Type: Application
    Filed: August 17, 2015
    Publication date: July 7, 2016
    Applicant: MARINE POLYMER TECHNOLOGIES, INC.
    Inventors: Sergio Finkielsztein, John N. Vournakis
  • Patent number: 9320653
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 26, 2016
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein